Cargando…
Protocol of an implementation study of a clinician intervention to reduce fear of recurrence in cancer survivors (CIFeR_2 implementation study)
BACKGROUND: Fear of cancer recurrence (FCR) affects 50–70% of cancer survivors with 30% reporting an unmet need for help with managing FCR. Patients indicate desire to discuss FCR with clinicians, however clinicians indicate discomfort with managing FCR and no formal educational interventions on how...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161179/ https://www.ncbi.nlm.nih.gov/pubmed/37147706 http://dx.doi.org/10.1186/s12909-023-04279-0 |
_version_ | 1785037437855072256 |
---|---|
author | Liu, Jia Serafimovska, Anastasia He, Sharon Butow, Phyllis Shaw, Joanne McHardy, Christopher John Harris, Georgia Butt, Zoe Beith, Jane |
author_facet | Liu, Jia Serafimovska, Anastasia He, Sharon Butow, Phyllis Shaw, Joanne McHardy, Christopher John Harris, Georgia Butt, Zoe Beith, Jane |
author_sort | Liu, Jia |
collection | PubMed |
description | BACKGROUND: Fear of cancer recurrence (FCR) affects 50–70% of cancer survivors with 30% reporting an unmet need for help with managing FCR. Patients indicate desire to discuss FCR with clinicians, however clinicians indicate discomfort with managing FCR and no formal educational interventions on how to discuss FCR or worry exists for oncology clinicians. Our team developed a novel clinician-driven brief education intervention to help patients manage FCR (the Clinician Intervention to Reduce Fear of Recurrence (CIFeR) intervention). In earlier work, we demonstrated the feasibility, acceptability, and efficacy of CIFeR in reducing FCR in breast cancer patients. We now aim to explore the barriers and facilitators to implementing this low-cost brief intervention within routine oncology practice in Australia. The primary objective is to assess the adoption of CIFeR in routine clinical practice. Secondary objectives are to identify the uptake and sustainability, perceived acceptability, feasibility, costs, barriers and facilitators of implementation of CIFeR in routine clinical practice, and to assess whether training in CIFeR increases clinicians’ self-efficacy in managing FCR with their patients. METHODS: This multicentre, single-arm Phase I/II implementation study will recruit medical and radiation oncologists and oncology surgeons who treat women with early breast cancer. Participants will complete online CIFeR training. They will then be asked to use CIFeR with suitable patients for the next 6 months. Participants will complete questionnaires prior to, immediately after and 3 and 6 months after training to assess confidence addressing FCR, and 3 and 6 months after training to assess Proctor Implementation outcomes. At 6 months, they will also be asked to participate in a semi-structured telephone interview to elicit their feedback about barriers and facilitators to using CIFeR in routine clinical practice. DISCUSSION: This study will provide further data to support the routine use of an evidence-based, clinician-lead educational intervention to reduce FCR in breast cancer patients. Additionally, this study will identify any barriers and facilitators to implementing the CIFeR intervention in routine care and evidence for integration of FCR training into oncology communication skills education. TRIAL REGISTRATION: Prospectively registered with the Australian New Zealand Clinical Trials Registry, ACTRN12621001697875. TRIAL SPONSOR: Chris O’Brien Lifehouse. PROTOCOL VERSION: 2.6, Dated 28th February 2023. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12909-023-04279-0. |
format | Online Article Text |
id | pubmed-10161179 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101611792023-05-06 Protocol of an implementation study of a clinician intervention to reduce fear of recurrence in cancer survivors (CIFeR_2 implementation study) Liu, Jia Serafimovska, Anastasia He, Sharon Butow, Phyllis Shaw, Joanne McHardy, Christopher John Harris, Georgia Butt, Zoe Beith, Jane BMC Med Educ Study Protocol BACKGROUND: Fear of cancer recurrence (FCR) affects 50–70% of cancer survivors with 30% reporting an unmet need for help with managing FCR. Patients indicate desire to discuss FCR with clinicians, however clinicians indicate discomfort with managing FCR and no formal educational interventions on how to discuss FCR or worry exists for oncology clinicians. Our team developed a novel clinician-driven brief education intervention to help patients manage FCR (the Clinician Intervention to Reduce Fear of Recurrence (CIFeR) intervention). In earlier work, we demonstrated the feasibility, acceptability, and efficacy of CIFeR in reducing FCR in breast cancer patients. We now aim to explore the barriers and facilitators to implementing this low-cost brief intervention within routine oncology practice in Australia. The primary objective is to assess the adoption of CIFeR in routine clinical practice. Secondary objectives are to identify the uptake and sustainability, perceived acceptability, feasibility, costs, barriers and facilitators of implementation of CIFeR in routine clinical practice, and to assess whether training in CIFeR increases clinicians’ self-efficacy in managing FCR with their patients. METHODS: This multicentre, single-arm Phase I/II implementation study will recruit medical and radiation oncologists and oncology surgeons who treat women with early breast cancer. Participants will complete online CIFeR training. They will then be asked to use CIFeR with suitable patients for the next 6 months. Participants will complete questionnaires prior to, immediately after and 3 and 6 months after training to assess confidence addressing FCR, and 3 and 6 months after training to assess Proctor Implementation outcomes. At 6 months, they will also be asked to participate in a semi-structured telephone interview to elicit their feedback about barriers and facilitators to using CIFeR in routine clinical practice. DISCUSSION: This study will provide further data to support the routine use of an evidence-based, clinician-lead educational intervention to reduce FCR in breast cancer patients. Additionally, this study will identify any barriers and facilitators to implementing the CIFeR intervention in routine care and evidence for integration of FCR training into oncology communication skills education. TRIAL REGISTRATION: Prospectively registered with the Australian New Zealand Clinical Trials Registry, ACTRN12621001697875. TRIAL SPONSOR: Chris O’Brien Lifehouse. PROTOCOL VERSION: 2.6, Dated 28th February 2023. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12909-023-04279-0. BioMed Central 2023-05-05 /pmc/articles/PMC10161179/ /pubmed/37147706 http://dx.doi.org/10.1186/s12909-023-04279-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Liu, Jia Serafimovska, Anastasia He, Sharon Butow, Phyllis Shaw, Joanne McHardy, Christopher John Harris, Georgia Butt, Zoe Beith, Jane Protocol of an implementation study of a clinician intervention to reduce fear of recurrence in cancer survivors (CIFeR_2 implementation study) |
title | Protocol of an implementation study of a clinician intervention to reduce fear of recurrence in cancer survivors (CIFeR_2 implementation study) |
title_full | Protocol of an implementation study of a clinician intervention to reduce fear of recurrence in cancer survivors (CIFeR_2 implementation study) |
title_fullStr | Protocol of an implementation study of a clinician intervention to reduce fear of recurrence in cancer survivors (CIFeR_2 implementation study) |
title_full_unstemmed | Protocol of an implementation study of a clinician intervention to reduce fear of recurrence in cancer survivors (CIFeR_2 implementation study) |
title_short | Protocol of an implementation study of a clinician intervention to reduce fear of recurrence in cancer survivors (CIFeR_2 implementation study) |
title_sort | protocol of an implementation study of a clinician intervention to reduce fear of recurrence in cancer survivors (cifer_2 implementation study) |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161179/ https://www.ncbi.nlm.nih.gov/pubmed/37147706 http://dx.doi.org/10.1186/s12909-023-04279-0 |
work_keys_str_mv | AT liujia protocolofanimplementationstudyofaclinicianinterventiontoreducefearofrecurrenceincancersurvivorscifer2implementationstudy AT serafimovskaanastasia protocolofanimplementationstudyofaclinicianinterventiontoreducefearofrecurrenceincancersurvivorscifer2implementationstudy AT hesharon protocolofanimplementationstudyofaclinicianinterventiontoreducefearofrecurrenceincancersurvivorscifer2implementationstudy AT butowphyllis protocolofanimplementationstudyofaclinicianinterventiontoreducefearofrecurrenceincancersurvivorscifer2implementationstudy AT shawjoanne protocolofanimplementationstudyofaclinicianinterventiontoreducefearofrecurrenceincancersurvivorscifer2implementationstudy AT mchardychristopherjohn protocolofanimplementationstudyofaclinicianinterventiontoreducefearofrecurrenceincancersurvivorscifer2implementationstudy AT harrisgeorgia protocolofanimplementationstudyofaclinicianinterventiontoreducefearofrecurrenceincancersurvivorscifer2implementationstudy AT buttzoe protocolofanimplementationstudyofaclinicianinterventiontoreducefearofrecurrenceincancersurvivorscifer2implementationstudy AT beithjane protocolofanimplementationstudyofaclinicianinterventiontoreducefearofrecurrenceincancersurvivorscifer2implementationstudy |